Panel & Audience Discussion: Evaluating Oral, Injectable & DNA Delivery Methods to Align Modality Selection with Clinical Performance & Commercial Scale
- Comparing modality trade-offs in potency, safety and half-life between oral small molecules and injectable peptide therapeutics to guide smarter development decisions
- Exploring how advances in oral delivery and next-generation formats to expand treatment options beyond injectables
- Discussing the manufacturing strengths and pitfalls of oral, DNA and injectable peptide therapies to align delivery mechanisms with commercial viability and faster routes to market